News releases from Eli Lilly and Company
Lilly Confirms Date and Conference Call for Second-Quarter 2021 Financial Results Announcement
July 22, 2021
Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2021 financial results on Tuesday, August 3, 2021. Lilly will also conduct a conference call on that day with the investment community...
Lilly and Incyte provide update on supplemental New Drug Application for baricitinib for the treatment of moderate to severe atopic dermatitis
July 16, 2021
Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today that the U.S. Food and Drug Administration (FDA) will not meet the Prescription Drug User Fee Act (PDUFA) action date for the...
Lilly and Banner Alzheimer's Institute collaborate on planned Phase 3 prevention trial of donanemab
July 15, 2021
Trial will include participants at risk for cognitive and functional decline related to Alzheimer's disease
Lilly Announces Acquisition of Protomer Technologies
July 14, 2021
Eli Lilly and Company (NYSE: LLY) today announced the acquisition of Protomer Technologies ("Protomer"), a private biotech company. Protomer's proprietary peptide- and protein-engineering platform is...
Breakthrough results for Jardiance® (empagliflozin) confirm EMPEROR-Preserved as first and only successful trial for heart failure with preserved ejection fraction
July 06, 2021
- The EMPEROR-Preserved phase III trial met its primary endpoint and demonstrated significant risk reduction with Jardiance for the composite of cardiovascular death or hospitalization for heart...
Lilly's SURPASS-1 results published in The Lancet show tirzepatide's superior A1C and body weight reductions versus placebo in adults with type 2 diabetes
June 26, 2021
Data presented at ADA's 81st Scientific Sessions® show the highest dose of tirzepatide (15 mg) reduced A1C by 2.07 percent and weight by 9.5 kg (20.9 lb., 11.0 percent)
Lilly announces call for Leonard Award nominations as part of global initiative celebrating 100 years of insulin
June 24, 2021
Lilly's donanemab receives U.S. FDA's Breakthrough Therapy designation for treatment of Alzheimer's disease
June 24, 2021
The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for donanemab, Eli Lilly and Company's (NYSE: LLY) investigational antibody therapy for Alzheimer's disease (AD)....
Lilly Launches Think Talk Treat Migraine™ to Help Improve Diagnosis and Treatment of Migraine
June 17, 2021
Think Talk Treat Migraine empowers people living with migraine and their primary care providers (PCPs) to have more direct conversations that can improve diagnosis and care
Lilly Announces Head-to-Head Study Comparing Once-Monthly Emgality® with Every-Other-Day Nurtec® ODT for the Preventive Treatment of Migraine
June 15, 2021
Eli Lilly and Company (NYSE: LLY) will participate in the Guggenheim Biopharma Strategy Series – Biopharma's Next Decade: Views from the Top on Global Strategy and Innovation – on Friday, June 18,...
Eli Lilly and Company (NYSE: LLY) will host a webcast on Thursday, July 1, 2021 to discuss the company's diabetes portfolio and its presentations at the American Diabetes Association's Virtual 81st...
Lilly Announces New Clinical Data from Verzenio and Oral SERD Programs at the American Society of Clinical Oncology Annual Meeting
June 04, 2021
New exploratory analysis of a pre-specified subgroup of patients with HR+, HER2- high risk early breast cancer who received neoadjuvant chemotherapy in the monarchE trial showed Verzenio plus endocrine...
Eli Lilly and Company (NYSE: LLY) will participate in the Goldman Sachs Healthcare Conference on June 9 and 10, 2021. Anne White, senior vice president and president, Lilly Oncology and Jake Van...
Lilly Reveals Critical Barriers to Optimal Migraine Care and Insights From Novel Clinical and Patient-Centric Real-World Evidence, Supporting Lilly's Preventive and Acute Treatment Portfolio at AHS 20
June 03, 2021
- Nearly half of people with migraine hesitated to seek care, choosing self-management and out of concern their disease would not be taken seriously, based on new findings from OVERCOME (U.S.), the...
Taltz® Showed Consistent, Long-Term Improvement in Key Signs and Symptoms of Axial Spondyloarthritis Through Two Years in Phase 3 Study
June 01, 2021
-- Most patients treated with Taltz did not show bone damage progression of radiographic axial spondyloarthritis up to two years in the long-term extension of two Phase 3 studies --
Lilly Announces Details of Presentations at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
May 19, 2021
New data from across Eli Lilly and Company's (NYSE: LLY) oncology portfolio will be presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 4-8, 2021. The data...
Eli Lilly and Company (NYSE: LLY) will participate in the UBS Global Healthcare Virtual Conference on Wednesday, May 26, 2021. Anat Ashkenazi, senior vice president and chief financial officer, will...
Eli Lilly and Company (NYSE: LLY) and MiNA Therapeutics Limited, a pioneer in RNA activation therapeutics, today announced a global research collaboration to develop novel drug candidates using MiNA's...
Lilly collaborates internationally with leading diabetes technology companies to integrate connected insulin pen solutions for people with diabetes
May 06, 2021
Partners offer app compatibility with Tempo Pen™ and Tempo Smart Button™ to help streamline diabetes management through automated data collection for insulin dose tracking
Eli Lilly and Company (NYSE: LLY) will participate in the Bank of America Securities 2021 Health Care Conference on Tuesday, May 11, 2021. Michael Mason, senior vice president, president of Lilly...
Lilly plans donation of COVID-19 therapies to Direct Relief for use in low- and lower-middle-income countries
May 04, 2021
- Environmental, Social and Governance (ESG) goals focus on key topics including access and affordability, diversity and inclusion, racial justice and the environment
Lilly accelerating baricitinib's availability in India following receipt of permission for restricted emergency use as a COVID-19 therapy via donations and licensing agreements
May 04, 2021
- Lilly is working with the Indian government to provide baricitinib donations in conjunction with the permission
Lilly Declares Second-Quarter 2021 Dividend and Announces Additional Share Repurchase Authorization
May 03, 2021
The board of directors of Eli Lilly and Company (NYSE: LLY) (the "Board") has declared a dividend for the second quarter of 2021 of $0.85 per share on outstanding common stock. The dividend is payable...
Taltz® Delivers More Cumulative Days with Completely Clear Skin for Adults with Psoriasis Compared to Seven Other Biologics in Novel Network Meta-Analysis
April 23, 2021
- Results from first network meta-analysis based on area under the curve of 52-week clinical trial data -
OLUMIANT® Showed Significant Improvements in the Severity and Extent of Atopic Dermatitis and Other Patient-Reported Outcomes in Phase 3 Study Analyses
April 23, 2021
- Extended safety analysis across eight studies helps further define the known safety profile of OLUMIANT 2-mg in atopic dermatitis -
Lilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study
April 20, 2021
- Results from two studies (BRAVE-AA1 and BRAVE-AA2) show statistically significant improvement in scalp hair regrowth across both baricitinib dosing groups, compared to placebo